Skip to main content Skip to section navigation Skip to footer
Sutro Logo high res
  • Who We Are
    • About Sutro
    • Leadership
      • Leadership Team
      • Board of Directors
      • Scientific Advisory Board
      • Clinical Advisory Board
    • Collaborations
  • Proprietary Platform
  • Pipeline
    • Overview
    • Scientific Publications
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Financials
    • Stock Data
    • Governance
    • IR Resources
  • Careers
    • The Way We Work
    • DEIB
    • Sustainability
    • Internships
    • Philanthropy
      • Employee Engagement
  • Contact Us

Press Releases

Investors

Investors

  • Overview
  • Press Releases
  • Events & Presentations
  • Financials
    • Financial Results
    • SEC Filings
    • Annual Reports
  • Stock Data
    • Quote & Chart
    • Historical Data
    • Analyst Coverage
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • IR Resources
    • FAQ
    • Email Alerts
    • Contact
Mar 4, 2020 7:00 am EST
Sutro Biopharma to Present Innovative Cancer Therapy Approach Using Precise Tumor Targeted Immunostimulants at World ADC London
Feb 27, 2020 7:00 am EST
Sutro Biopharma to Present at the Cowen and Company 40th Annual Health Care Conference
Feb 5, 2020 7:30 am EST
Sutro Biopharma Expands Senior Management Team with the Appointments of Vice President of Immunobiology and Vice President of Business Development
Jan 9, 2020 7:00 am EST
Sutro Biopharma to Present at 38th Annual J.P. Morgan Healthcare Conference
Jan 8, 2020 9:26 am EST
Sutro Biopharma Appoints James Panek to Board of Directors
Nov 26, 2019 7:00 am EST
Sutro Biopharma to Participate in the 31st Annual Piper Jaffray Healthcare Conference
Nov 19, 2019 7:00 am EST
Sutro Biopharma to Present at the Stifel 2019 Healthcare Conference
Nov 8, 2019 7:00 am EST
Sutro Biopharma Reports Third Quarter 2019 Financial Results and Recent Business Highlights and Developments
Oct 29, 2019 7:00 am EDT
Sutro Biopharma Presents Encouraging Preliminary Clinical Data in Ongoing Phase I Study for STRO-002 Antibody-Drug Conjugate in Patients with Advanced Ovarian Cancer
Oct 16, 2019 4:35 pm EDT
Sutro Biopharma Announces Presentation of STRO-002 for the Potential Treatment of Ovarian and Endometrial Cancer at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 11
  • Page 12
  • Page 13
  • Page 14
  • Page 15
  • Page 16
  • Page 17
  • Page 18
  • Page 19
  • Page 20
  • …
  • Page 23
  • Next Pagearrow_forward
rss_feed News RSS
  • emailEmail Alerts
  • contact_pageContacts
  • rss_feedRSS News Feed
Sutro Biopharma Corporate Site

Dedicated to patients
and changing the future of oncology

  • Follow
  • Follow
  • Follow
  • Follow

Follow us on social media

© 2025 Sutro Biopharma, Inc.
South San Francisco, California, U.S.A.

SITE MAP | PRIVACY POLICY | EMAIL ALERTS | CONTACT US | VISITOR GUIDE

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

Sutro Biopharma, Inc.
Powered by GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.